alexa Dendrimers As Carriers Of Anti-leukemia Drugs
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Nanotek & Expo
December 01-03, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Barbara Klajnert-Maculewicz
Accepted Abstracts: J Nanomed Nanotechnol
DOI: 10.4172/2157-7439.S1.019
Anticancer drugs such as cytarabine (araC) belong to nucleoside analogues (NAs). NAs are commonly used in the treatment of acute myeloid leukemia, acute lymphocytic leukemia, and lymphomas. AraC acts by interfering with newly synthesized nucleic acids or by modifying physiological nucleosides metabolism. Like most nucleoside analogs, araC is administered as an inactive prodrug and requires specialized nucleoside transporters to cross plasma membranes. Inside a cell, araC is activated to cytotoxic 5?-triphosphates form (araCTP) by intracellular kinases. Unfortunately, a therapy based on cytarabine has its limitations due to several primary and acquired resistance mechanisms that arise during prodrug activation steps. It may lead to inefficient concentration of the therapeutics in cancer cells. Carrier systems that would deliver active forms of NAs are currently seeking. It has been demonstrated that polypropylene imine (PPI) dendrimers with a partially modified surface by maltose residues (PPI-m) easily form complexes with negatively charged 5?-triphosphates of nucleoside analogues. It happens due to the presence of protonated primary and tertiary amino groups. PPI-m dendrimers are nontoxic and highly biocompatible. Moreover, PPI-m dendrimers protect bound drug molecules from enzymatic degradation. Complexes of araCTP and PPI-m dendrimers show enhanced cytotoxic activity against an acute myeloid lukemia cell line 1301 in comparison with free cytarabine and 5?-triphosphate of cytarabine. Thus, PPI-m dendrimers improve stability of NAs and efficiently deliver the active drug forms directly to cancer cells. To sum up, maltose-modified polypropylene imine dendrimers are attractive systems as anticancer drug carriers, especially with a vision to apply them when drug-resistance occurs.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version